Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- You have a known BRCA1 or BRCA2 mutation (either inherited or found in the tumor).
- You are about to start Olaparib (a PARP inhibitor) as your first maintenance treatment, possibly with bevacizumab.
- You are 18 years or older.
- You have a good performance status (WHO score 0 or 1, meaning you are able to carry on normal activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This research study examines circulating tumor cells (cancer cells in the bloodstream) to better understand which patients might benefit from PARP inhibitor drugs. You'll have blood samples collected to help doctors personalize cancer treatment decisions.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This trial tests whether a supervised exercise program combined with nutrition counseling can help women with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. It aims to improve quality of life and physical function during treatment.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.